Zomagen Biosciences Ltd, a wholly owned subsidiary of Ventyx Biosciences (VTYX), received FDA orphan designation for a treatment of pericarditis, according to a post to the agency’s website.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTYX:
- Largest borrow rate increases among liquid names
- Ventyx Biosciences Sets March 3, 2026 Vote on Eli Lilly $14-Per-Share Cash Merger
- Ventyx Biosciences call volume above normal and directionally bullish
- Ventyx Biosciences Sets Special Cash Bonuses Amid Lilly Merger
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!